NEW YORK CITY, NY / ACCESS Newswire / November 16, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Candel Therapeutics, Inc. ("Candel Therapeutics, Inc.") (NASDAQ:CADL) concerning potential violations of the federal securities laws.
Candel Therapeutics, Inc. shares fell roughly 26% on November 13, 2026, following the Company's disclosure that it now expects to submit its Biologics License Application (BLA) for aglatimagene in localized prostate cancer in mid-2027, instead of the previously indicated fourth quarter of 2026. Management attributed the delay to timelines associated with certain assay refinement and ongoing dialogue with the FDA. On the same day, the Company reported a quarterly net loss of $21.9 million, a nine-month net loss of $69.6 million, and announced a new $50 million at-the-market equity program. This updated timeline contrasted with earlier statements. On August 13, 2026, the Company indicated in its quarterly Form 8-K filing that critical activities were progressing to enable the anticipated BLA submission in Q4 2026. The investigation concerns whether Candel Therapeutics, Inc. adequately disclosed risks related to assay refinement timelines and FDA dialogue ahead of November 12, 2026.
If you purchased NASDAQ:CADL securities and suffered a loss, contact the firm to review your shareholder rights or call at (212) 363-7500 to speak to our team.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire